19 August 2022
According to RIA Novosti report, Veronika Skvortsova, the head of the FMBA, stated the FMBA is presenting two new drugs for leprosy and malaria at the exhibition of the Army-2022 forum.
She noted that the focus of FMBA work is not import substitution but on keeping ahead of imports, creating domestic technologies based on its own know-how. “Today we are showing two new drugs, against leprosy and malaria, at the exhibition,” Skvortsova said in an interview.
She also said that clinical trials of the Mir-19 coronavirus drug for outpatient use have been completed, and the drug may appear on the market at the end of August.
“They have been completed. We are now making a report to expand the indications for use. Currently, this work is underway, and we may hope that it will come in the market at the end of August,” Skvortsova told reporters answering a question about how the research on Mir–19 drug for outpatient use was going.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Research calls for greater investment in Alzheimer’s clinical trials
03 May 2024
Stress impact on protein particle formation for monoclonal antibody formulation
03 May 2024
Health Ministry registered Russian drug for ankylosing spondylitis
02 May 2024
Production of finished drugs in Russia grew by 13.8%
02 May 2024